Highlights in Medicinal Chemistry II


SCI, London, UK
Wednesday 23 November 2016
Organised by SCI’s Fine Chemicals Group

Click here to go to "book me on event" button


This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focused forum to promote examples of medicinal chemistry excellence.


This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.


09.00   Registration and refreshments
09.50   Opening remarks
09.55   The realisation of activity-directed synthesis
Prof Adam Nelson, University of Leeds
10.35   Structure-based design of drug-like macrocycles to probe the role of MTH1 in cancer
Dr Jason Kettle, AstraZeneca
11.15   Refreshment break
11.35   Development of novel, selective and irreversible PI3K inhibitors
Mr Samuel Dalton, University of Strathclyde, GlaxoSmithKline
12.00   Discovery of the first cell-active inhibitors of poly(ADP ribose) glycohydrolase (PARG) through high-throughput screening and computational approaches
Dr Kate Smith, Cancer Research UK Manchester Institute
12.25   Discovery of a small molecule that mitigates hearing loss in a model of Usher syndrome III
Dr Karine Malagu, Discovery from Charles River
12.50   Lunch
13.50   Discovery of novel TACE inhibitors for topical treatment of psoriasis
Dr Gilles Ouvry, Galderma
14.15   Discovery of CCT251921: A potent, selective and orally bioavailable small molecule modulator of the mediator complex-associated kinases CDK8 and CDK19
Dr Aurélie Mallinger, The Institute of Cancer Research
14.40   Increasing solubility for free
Dr Timothy Ritchie, TJR-Chem
15.20   Refreshment break
15.40   Extracting actionable knowledge from large scale in vitro pharmacology data
Dr Al Dossetter, MedChemica
16.05   Receptor kinetics vs CNS exposure: which is more important for a ghrelin inverse agonist
Dr William McCoull, AstraZeneca
16.30   Chemical probes for epigenetic proteins
Prof Paul Brennan, University of Oxford
17.10   Closing remarks
17.15   Wine reception

Please click here to view the event flyer.

Organising Committee

Joanne Pinder, SCI/Vertex Pharmaceuticals Eur Ltd
Sarah Major, SCI/Evotec (UK) Ltd
Iain Simpson, SCI/AstraZeneca
Mihiro Sunose, SCI/Sygnature Discovery Ltd
Nigel Swain, SCI/Pfizer


If you are interested in in sponsorship opportunities, please contact conferences@soci.org.

Delegate Fees

Early Bird fee - before 7 October 2016

GB£90 . . . . . . . . . SCI Member
GB£40. . . . . . . . . .SCI Student Member
GB£130 . . . . . . . . Non Member

Standard fee - from 7 October 2016

GB£110. . . . . . . . .SCI Member
GB£50. . . . . . . . . .SCI Student Member
GB£155. . . . . . . . .Non Member

For booking terms and conditions click here.

Location map and travel

14/15 Belgrave Square

Please click here for a location map and travel information.

For more information, please contact:

SCI logo

Conference Team
T: +44 (0)20 7598 1561
E: conferences@soci.org


AstraZeneca logoevotec logo

Related Links

  • Protein-Protein Interactions 2016 - 5 - 6 December 2016
  • Other Fine Chemicals Group Events